Cambridge, MA September 10, 2012 Visterra, Inc., developer of novel therapeutics to treat major diseases, today announced the presentation of positive data from a preclinical study evaluating the efficacy of the company's lead product candidate, VIS410, a broadly protective, fully human monoclonal antibody being developed for influenza A infections. Data from preclinical studies were presented today at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These data were also selected by ICAAC to be included in the public communication highlights for the meeting.
Developed using Visterra's innovative platform, VIS410 targets a site on influenza hemagglutinin (HA) that is present across all influenza A subtypes and is resistant to mutation development. VIS410 demonstrated broad neutralization against all influenza A strains tested in vitro, and provided potent and specific protection in mouse models against a lethal dose of influenza A virus, both prophylactically and therapeutically. In prophylactic studies, 100% of healthy non-infected mice who received a single dose of VIS410 survived subsequent infection with either H1N1 or H3N2 influenza A virus. In post-infection therapeutic studies, 100% of mice treated with a single dose of VIS410 survived a lethal viral challenge of either H1N1 or H3N2 when antibody was administered up to 72 hours after infection.
"This data with VIS410 shows several ways that this drug candidate has promise for fighting influenza, including possible pandemic strains," said Donna Ambrosino, M.D., Chief Medical Officer of Visterra. "With VIS410, we have designed an antibody that targets the viral hemagglutinin protein (HA) to enable to healthy person or patient to prevent or treat an established infection. Secondly, we have designed VIS410 as an antibody that neutralizes both groups of viral strains for influenza A, Group 1 and Group 2 viruses, opening the pot
|Contact: Kathryn Morris|
The Yates Network